Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia — Stella

Home/Acute Lymphoblastic Leukemia, in Relapse/

View on ClinicalTrials.gov

Recruiting

Back to Acute Lymphoblastic Leukemia, in Relapse trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Brazil

Instituto do Cancer do Estado de Sao Paulo, São Paulo, São Paulo

Key details

Phase

Safety & dosing

Sponsor

Instituto do Cancer do Estado de São Paulo

Collaborators

Libbs Farmacêutica LTDA

Enrollment target

~50 participants

Started

April 2024

Primary completion

August 2028

Age range

16 Years – 60 Years

Last updated May 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.